Back to top
more

CV Sciences (CVSI)

(Delayed Data from OTC)

$0.04 USD

0.04
274,474

0.00 (-4.91%)

Updated Apr 18, 2024 03:43 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

CV Sciences, Inc. (CVSI) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

CV Sciences, Inc. (CVSI) delivered earnings and revenue surprises of 50% and 6.81%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

CV Sciences, Inc. (CVSI) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

CV Sciences, Inc. (CVSI) delivered earnings and revenue surprises of 0% and 15.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

VAXART, INC. (VXRT) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

VAXART, INC. (VXRT) delivered earnings and revenue surprises of -9.52% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Ardelyx (ARDX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ardelyx (ARDX) delivered earnings and revenue surprises of 0% and 307.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Amneal Pharmaceuticals (AMRX) Lags Q4 Earnings Estimates

by Zacks Equity Research

Amneal (AMRX) delivered earnings and revenue surprises of -5.26% and 1.28%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Here's Why CV Sciences, Inc. (CVSI) Looks Ripe for Bottom Fishing

by Zacks Equity Research

CV Sciences, Inc. (CVSI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

CV Sciences, Inc. (CVSI) Reports Break-Even Earnings for Q3

by Zacks Equity Research

CV Sciences, Inc. (CVSI) delivered earnings and revenue surprises of 100.00% and -7.98%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Will CV Sciences, Inc. (CVSI) Report Negative Q3 Earnings? What You Should Know

by Zacks Equity Research

CV Sciences, Inc. (CVSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CV Sciences, Inc. (CVSI) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

CV Sciences, Inc. (CVSI) delivered earnings and revenue surprises of 0.00% and 0.24%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Will CV Sciences, Inc. (CVSI) Report Negative Q2 Earnings? What You Should Know

by Zacks Equity Research

CV Sciences, Inc. (CVSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will CV Sciences, Inc. (CVSI) Report Negative Q1 Earnings? What You Should Know

by Zacks Equity Research

CV Sciences, Inc. (CVSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CV Sciences, Inc. (CVSI) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

CV Sciences, Inc. (CVSI) delivered earnings and revenue surprises of -350.00% and -22.52%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Will CV Sciences, Inc. (CVSI) Report Negative Q4 Earnings? What You Should Know

by Zacks Equity Research

CV Sciences, Inc. (CVSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CV Sciences, Inc. (CVSI) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

CV Sciences, Inc. (CVSI) delivered earnings and revenue surprises of -50.00% and -11.93%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Will CV Sciences, Inc. (CVSI) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

CV Sciences, Inc. (CVSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate CV Sciences, Inc. (CVSI) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

CV Sciences, Inc. (CVSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sweta Killa headshot

Why Small-Cap ETFs & Stocks Outperformed Last Week

by Sweta Killa

Given the improvements in domestic economy, small-cap stocks led the way higher last week.

CV Sciences Inc (CVSI) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

CV Sciences Inc (CVSI) delivered earnings and revenue surprises of -66.67% and 37.83%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate CV Sciences, Inc. (CVSI) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

CV Sciences, Inc. (CVSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CV Sciences, Inc. (CVSI) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

CV Sciences, Inc. (CVSI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

CV Sciences, Inc. (CVSI) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

CV Sciences, Inc. (CVSI) delivered earnings and revenue surprises of -250.00% and -18.91%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: CV Sciences, Inc. (CVSI) Q4 Earnings Expected to Decline

by Zacks Equity Research

CV Sciences, Inc. (CVSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CV Sciences, Inc. (CVSI) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

CV Sciences, Inc. (CVSI) delivered earnings and revenue surprises of -300.00% and -32.29%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate CV Sciences, Inc. (CVSI) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

CV Sciences, Inc. (CVSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CV Sciences, Inc. (CVSI) Meets Q2 Earnings Estimates

by Zacks Equity Research

CV Sciences, Inc. (CVSI) delivered earnings and revenue surprises of 0.00% and -3.44%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?